News versetzen ABIO in ein neues Zeitalter

Thema bewerten
Beiträge: 134
Zugriffe: 15.713 / Heute: 2
Arca Biopharma kein aktueller Kurs verfügbar
 
Brueller:

News versetzen ABIO in ein neues Zeitalter

4
26.03.10 16:03
March 26, 2010 - 8:30 AM EDT

      ABIO§5.60    2.95


ARCA biopharma Announces Patent Issued for Treating Heart Failure Patients with Bucindolol Based on Genetic Testing
Revised Request for FDA Special Protocol Assessment for GencaroTM Development in Genotype-defined Heart Failure Population Submitted
Mar. 26, 2010 (Business Wire) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing. The patent (USP# 7,678,824) entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting,” provides protection in the United States for this novel approach to treating patients with heart failure, one of the largest health care problems in the United States and the rest of the world. ARCA had previously announced the notice of allowance of this patent. Industry sources estimate that approximately 5.7 million Americans have heart failure and nearly 670,000 new patients are diagnosed annually. In addition, heart failure is the underlying reason for approximately 12 to 15 million annual visits to physicians, 6.5 million annual hospital days and over $37 billion in direct and indirect healthcare costs in the United States.

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

>4x bewertet
108 Beiträge ausgeblendet.
Seite: Übersicht Alle 1 2 3 4 5 6


Werbung

Entdecke die beliebtesten ETFs von Amundi

Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Russell 1000 Growth UCITS ETF - Acc
Perf. 12M: +38,69%
Amundi DJ Global Titans 50 UCITS ETF - Dist
Perf. 12M: +31,27%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +30,70%
Amundi MSCI World II UCITS ETF - USD Hedged Dist
Perf. 12M: +29,06%

Weltenbumml.:

Konsollidierung bald abgeschlossen!

 
15.04.10 16:04
Könnte heute mit 20 - 30 % Plus aus dem handel gehen.
Bewerten
Weltenbumml.:

Shorties werden bald verglühen!

 
15.04.10 16:15
Nach der erhöhung des Kapitals und des Streubesitz, sollte der Markt nun dies im Kurs verarbeitet haben.
Bewerten
Weltenbumml.:

Umsätze in den letzten Tagen! Massivst rückläufig.

 
15.04.10 16:18
ARCA biopharma Raises $6.8 Million in First Quarter of 2010 Through At-The-Market Offering of Common Stock

BROOMFIELD, Colo., Apr 01, 2010 (BUSINESS WIRE) --ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market.

"The proceeds from this equity offering, together with the actions we have previously taken to reduce costs, have significantly improved ARCA's financial position," said Patrick Wheeler, Acting Chief Financial Officer of ARCA. "The additional equity also improves our balance sheet, which we believe will allow us to regain compliance with NASDAQ's Continued Listing Standards."

Wedbush PacGrow Life Sciences acted as ARCA's sales agent for these transactions. The shares were issued pursuant to ARCA's shelf registration statement. A prospectus supplement relating to the common stock offering was filed with the Securities and Exchange Commission on December 8, 2009. As of December 31, 2009, the Company had 7,620,448 shares of common stock outstanding.

About ARCA biopharma

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Weltenbumml.:

Vor 1Woche wurde in 1 Std. 2 Mio Stück gehandelt

 
15.04.10 16:36
Jetzt noch nicht mal 100.000 Stück. Das bedeutet das der Verkaufsdruck eingebrochen ist. Wert ist schon wieder über Verkauft. Das Zeigen auch andere Indikatoren.
Bewerten
Weltenbumml.:

Ich habe gestern und heute mein Depot um 6.000 Stk

2
15.04.10 16:43
Aufgestockt und werde biss ende der Woche nochmal biss zu 10.000 Stücke einsammeln. Mein Kursziel biss jahresende liegt bei 65 Dollar.
Bewerten
>2x bewertet
Weltenbumml.:

Ab 18-20.00 Uhr ist der Ausverkauf abgeschlossen!

 
15.04.10 17:12
Bewerten
>1x bewertet
Flensburger03:

Bist Du ein Träumer

 
15.04.10 17:30
Wie kommst Du auf 65 Dollar,was sollen da denn für Nachrichten kommen,ich wäre froh wenn wir 10Dollar sehen.
Habe auch ein par in meinem Depot
Bewerten
>1x bewertet
derChandler:

65 Dollar...

 
15.04.10 18:36
... ich träume gerne mit ;-)
Bewerten
Anzeige: Der CEO kauft ein – und das gleich zweimal

Startschuss für die nächste Kursrallye?
Flensburger03:

Was passiert Hier

 
23.04.10 18:06
Gibt es neue Nachrichten,oder wird es nur ein beruhigenes Wochenende
Bewerten
derChandler:

Kursanstieg

 
24.04.10 11:05
Es gibt keine neuen Nachrichten. Der Kursanstieg ist wohl auf ein Gerücht zurückzuführen, das im Umlauf ist.
Es geht um, dass das "Approval" für Gencaro durch ist. Aber wie gesagt, nur ein Gerücht!

Ich frage mich halt, ob ein Gerücht so einen explosionsartigen Handel auslösen kann.
Vielleicht wissen da einige schon mehr ;-)

Sollte es war sein, wird es weiter nach Norden gehen. Der Montag wird es uns zeigen.

Schönes Wochenende

Chandler
Bewerten
>1x bewertet
derChandler:

gute News! Schaut auf den Kursanstieg!

 
17.05.10 15:53
Bewerten
>1x bewertet
Weltenbumml.:

Über 30 % Kursanstieg

 
17.05.10 16:25
Bewerten
Weltenbumml.:

Ich vermute das der Kurs nach Börsenschluss massiv

 
17.05.10 19:40
Ansteigen wird.
Bewerten
onkel james:

Arca gestern mit super News

 
31.01.13 08:18
und massiven Kursanstieg !

Nachbörslich sogar hoch bis 0,74 US Dollar !

Chart offen, mal sehen ob es heute weiter geht !
Bewerten
>1x bewertet
wes_:

wow! $.85

 
31.01.13 15:52
Bewerten
wes_:

ABIO Chart $.94

 
31.01.13 16:01
(Verkleinert auf 56%) vergrößern
News versetzen ABIO in ein neues Zeitalter 574419
Bewerten
Filbiremus:

News: Dec. 12, 2012, 10:30 a.m. EST

 
02.02.13 14:33
www.marketwatch.com/story/...urnal-of-heart-failure-2012-12-12

Dec. 12, 2012, 10:30 a.m. EST
CORRECTING AND REPLACING Gencaro(TM) Cardiovascular Effect on Patients with Atrial Fibrillation Paper Published in European Journal of Heart Failure

BROOMFIELD, Colo., Dec 12, 2012 (BUSINESS WIRE) -- First graph of release should read: ARCA biopharma, Inc. ABIO -24.68% , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published in the European Journal of Heart Failure ( www.escardio.org/journals/european-journal-heart-failure ), a publication of the Heart Failure Association of the European Society of Cardiology (sted ARCA biopharma, Inc. (Nasdaq: ABIO) announces the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published).

The corrected release reads:

GENCARO(TM) CARDIOVASCULAR EFFECT ON PATIENTS WITH ATRIAL FIBRILLATION PAPER PUBLISHED IN EUROPEAN JOURNAL OF HEART FAILURE

ARCA biopharma, Inc. ABIO -24.68% , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Effect of Bucindolol (Gencaro) on Heart Failure Outcomes and Heart Rate Response in Patients with Reduced Ejection Fraction Heart Failure and Atrial Fibrillation" was published in the European Journal of Heart Failure ( www.escardio.org/journals/european-journal-heart-failure ), a publication of the Heart Failure Association of the European Society of Cardiology.

The paper discusses post-hoc analyses of data from the Phase 3 clinical study of Gencaro in heart failure, known as the Beta-Blocker Evaluation of Survival Trial (BEST), which was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs. These data demonstrate that patients with established atrial fibrillation (AF) in BEST who received Gencaro had improvements in heart failure clinical endpoints. Compared to placebo, the effects of Gencaro on improving heart failure clinical endpoints in the 303 patients in BEST with established AF were generally similar to the effects of Gencaro on these endpoints in the 2,176 patients in BEST with normal sinus rhythm.

The data also demonstrate that Gencaro made it more likely for patients with established AF to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those AF patients who did achieve rate control. 67% of AF patients who received Gencaro achieved ventricular response rate control, defined as a resting heart rate of less than or equal to 80 beats per minute without symptomatic bradycardia (p < 0.005). In AF patients who achieved ventricular response rate control, Gencaro produced a 39% reduction (p = 0.025) in cardiovascular mortality/cardiovascular hospitalizations. In addition, Gencaro also improved cardiovascular clinical endpoints for those AF patients possessing the genotype which ARCA believes is most favorable for Gencaro response. In a substudy of 1,040 patients in BEST in which patient genotypes were analyzed, Gencaro was associated with a 72% decrease (p = 0.039) in cardiovascular mortality/cardiovascular hospitalizations in those 52 AF patients in the substudy with the beta-1 389 arginine homozygous genotype. ARCA believes that this genotype predicts a favorable response to Gencaro, and is estimated to be present in about 50% of the population in the U.S. These data are in contrast to the data reported for studies of other beta-blockers, including carvedilol, in which AF patients with the beta-1 389 arginine homozygous genotype who received those drugs exhibited evidence of resistance to heart rate reduction.

Christopher O'Connor, MD, Professor of Medicine and Cardiologist, Duke University Medical Center, and a co-author of the paper commented, "In placebo controlled trials of patients with heart failure and reduced left ventricular ejection fraction (HFREF) who also have permanent AF, currently approved beta blockers have not shown benefit by improving clinical endpoints. In this study, Gencaroexhibited evidence of efficacy against clinical endpoints in patients with HFREF and AF. In addition, this efficacy appears to be pharmacogenetically enhanced in patients with the beta-1 389 arginine homozygous genotype, and rate control was also effective in this genotype. This evidence of rate control by Gencaro in this genotype is important because it has been reported that other beta-blockers do not provide adequate rate control in AF patients with this genotype."

Michael Bristow, MD, PhD, President and CEO of ARCA biopharma and Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus, and a senior author of the paper added, "These data from the BEST study suggest that Gencaro may be safe and effective in patients with permanent AF. ARCA would be able to further test this hypothesis in its proposed trial of Gencaro in AF prevention."

ARCA has been granted patents in the U.S., Europe, and other jurisdictions for methods of identifying and treating patients with the beta-1 389 arginine homozygous genotype. The Company plans to conduct a Phase 3 clinical trial to evaluate Gencaro as a potential treatment for the prevention of AF in patients with this genotype, subject to receiving the necessary funding.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information please visit www.arcabiopharma.com .

Safe Harbor Statement

This press release and the associated presentation may contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the SEC, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: ARCA biopharma, Inc.


       
       ARCA biopharma, Inc.
       Christopher D. Ozeroff
       Senior Vice President and General Counsel
       720-940-2100
       



Copyright Business Wire 2012

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Filbiremus:

News:Jan. 3, 2013, 9:00 a.m. EST

 
02.02.13 14:35
Jan. 3, 2013, 9:00 a.m. EST
Gencaro(TM) Effect on Reducing Ventricular Arrhythmias Paper Published in Circulation: Arrhythmia and Electrophysiology

BROOMFIELD, Colo., Jan 03, 2013 (BUSINESS WIRE) -- ARCA biopharma, Inc. ABIO -24.68% , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced that the paper "Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias with Bucindolol in Patients with Chronic Heart Failure" was published in the journal Circulation: Arrhythmia and Electrophysiology [ circep.ahajournals.org/content/early/recent ], a publication of the American Heart Association. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado Anschutz Medical Campus.

The paper analyzes the overall and pharmacogenetic effects of Gencaro (bucindolol) in reducing the incidence of serious ventricular arrhythmias. The authors based their conclusions on post-hoc analyses of clinical data from a 1040 patient DNA substudy of the Phase 3 clinical trial Beta-Blocker Evaluation of Survival Trial (BEST). The BEST Trial was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs.

The paper shows that patients in the BEST Trial who received Gencaro experienced a 58% reduction in the incidence of ventricular tachycardia or fibrillation ("VT/VF") (p = 0.00006), adjusted for the competing risk of mortality. In addition, the authors determined that Gencaro reduced the incidence of VT/VF by 74% (p = 0.00005) in patients with the beta-1 389 arginine homozygous genotype, believed to be present in about 50% of the U.S. population.

The study also analyzed the effect of two other genotypes on Gencaro's effect on VT/VF. Based on a statistically significant test for interaction (p = 0.03), the three genotypes provide a potential method for identifying VT/VF patients for therapy. The first group is the approximately 50% of patients with the beta-1 389 arginine homozygous genotype, who had an enhanced response (event rate reduction by 74%); the next group is the approximately 40% of patients with a second genotype (beta-1 389 glycine carriers + alpha-2C 322-325 wild type homozygous) who had an intermediate response (event rate reduction by 49%) to Gencaro; and the remaining group is the approximately 10% of patients with a third genotype (beta-1 389 glycine carriers + alpha-2C 322-325 Deletion carriers), that had no response. This pharmacogenetic approach therefore defines a target population for Gencaro that has a potentially enhanced response, as well as a small subpopulation that may not benefit from therapy; the genetic identification of such "outliers" in drug response is a major goal of pharmacogenetics.

Stuart Connolly, M.D., of McMaster University, an electrophysiologist-cardiologist, commented: "I believe that beta-blockers have only modest effects on prevention of serious ventricular arrhythmias, but in the Aleong et al study, patients with the higher activity beta-1 receptor genetic variant (389 arginine homozygous) had a significant (by 74%, p = 0.00005) and genotype specific reduction in the risk of ventricular tachycardia or fibrillation. This suggests that bucindolol may have clinically important anti-ventricular arrhythmic effects in the roughly 50% of patients who have the beta-1 389 arginine homozygous genotype, and I believe that further study of bucindolol in additional clinical trials is warranted."

Will Sauer, M.D., from the University of Colorado Anschutz Medical Campus, an electrophysiologist-cardiologist and a co-author on the paper, said: "While the use of beta-blockers as a class of drugs for prevention of ventricular arrhythmias is not well studied, it is commonly thought that any beta-blocker is potentially helpful for any at-risk patient. However, the research presented in our Circulation AEP paper shows that patients with the beta-1 389 arginine homozygous adrenergic receptor polymorphism experienced a 74% reduction in VT/VF events with the beta-blocker/sympatholytic agent bucindolol. I believe that these findings have important implications for the personalized treatment of patients at risk for arrhythmias. In the future, physicians may look at a patient's genotype prior to the initiation of a particular beta-blocker or other anti-arrhythmic. I believe that this is particularly important in the prevention of lethal arrhythmias like VT or VF, where the current practice of assuming that any beta-blocker may work could be harmful; for example, if the prescribed beta blocker is not efficacious or if a more efficacious beta-blocker for that patient is available."

Michael Bristow, M.D., Ph.D., Cardiologist/clinical pharmacologist and senior author on the paper, CEO of ARCA, also commented: "This 74% reduction in VT-VF in the beta-1 389 Arg/Arg subpopulation suggests that Gencaro warrants further study, such as in heart failure/reduced left ventricular ejection fraction patients at risk for ventricular arrhythmias, who have implanted cardioverter-defibrillators that are having appropriate firing. This could constitute another indication for Gencaro beyond those of atrial fibrillation prevention and heart failure."

Ventricular tachycardia and ventricular fibrillation are serious, potentially life-threatening arrhythmias, and the most common cause of sudden cardiac arrest.

ARCA has been granted patents in the U.S., Europe, and other jurisdictions for methods of identifying and treating patients with the beta-1 389 arginine homozygous genotype. The Company plans to conduct a Phase 3 clinical trial to evaluate Gencaro as a potential treatment for the prevention of AF in patients with this genotype, including measuring VT/VF data as a secondary endpoint, subject to receiving the necessary funding.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more information, please visit www.arcabiopharma.com .

Safe Harbor Statement

This press release and the associated presentation may contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, Gencaro's potential to treat ventricular tachycardia or ventricular fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the SEC, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: ARCA biopharma, Inc.


       
       ARCA biopharma, Inc.
       Christopher D. Ozeroff, 720-940-2100
       Senior Vice President and General Counsel
       



Copyright Business Wire 2013

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Filbiremus:

News:Jan. 29, 2013, 5:00 p.m. EST

 
02.02.13 14:36
Jan. 29, 2013, 5:00 p.m. EST
New Adaptive Phase 3 Trial Planned for Gencaro(TM) in Atrial Fibrillation

BROOMFIELD, Colo., Jan 29, 2013 (BUSINESS WIRE) -- ARCA biopharma, Inc. ABIO -24.68% , a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, today provided an update on a proposed, genetically-targeted clinical trial in atrial fibrillation ("AF") of the Company's lead developmental drug, Gencaro (bucindolol hydrochloride). The Company also announced that Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, has signed a non-binding Letter of Intent to collaborate on the initial, Phase 2B portion of the proposed trial.

The Proposed GENETIC-AF Phase 3 Adaptive Design Clinical Trial

Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »

Bewerten
Filbiremus:

CEO kauft am 25-Jan-13 für $500,000.00 Aktien...

 
02.02.13 14:46
Bewerten
Filbiremus:

News:04.02.2013

 
04.02.13 12:23
Bewerten
MilchKaffee:

ist hier noch jemand dabei?

 
07.02.13 11:01
Bewerten
onkel james:

Ja ich !

 
07.02.13 11:26
Gestern nachbörslich mit guten News und + 11 % auf 0,71 Dollar und 200k Volumen !

Könnte heute zu einem erneuten Run kommen.

Überlege hier nochmal nachzulegen.
Bewerten
>1x bewertet
MilchKaffee:

ich weiss nicht warum, aber bei mir wird 0.83 als

 
07.02.13 11:52
marktpreis angezeigt...
Bewerten
MilchKaffee:

Premarket +24,62% 0.81

 
07.02.13 15:10
Bewerten
Es gibt keine neuen Beiträge.
 Ich: 

Seite: Übersicht Alle 1 2 3 4 5 6

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Arca Biopharma Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
2 101 Arca BioPharma iwanooze iwanooze 25.04.21 01:06
4 133 News versetzen ABIO in ein neues Zeitalter Brueller MilchKaffee 07.02.13 15:10
  32 Ab 5,8 ist sie nicht mehr zu halten. Weltenbummler Weltenbummler 17.05.10 15:26
2 7 Wer kennt ARCA-BIOPHARMA? Abachonär Weltenbummler 26.03.10 15:58